Patients with hemodialysis-induced hypoxemia had a poor prognosis of COVID-19

Renal Replacement Therapy - Tập 8 Số 1 - 2022
Masataro Toda1, Ayumi Yoshifuji1, Kentaro Fujii1, Motoaki Komatsu1, Atsushi Kato1, Ikue Tamura1, Wataru Sugi1, Munekazu Ryuzaki1
1Department of Nephrology, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo, 108-0073, Japan

Tóm tắt

Abstract Background We experienced that some hemodialysis (HD) patients with coronavirus disease 2019 (COVID-19) exacerbated hypoxemia during HD. Though HD-induced hypoxemia has been reported, there have been no reports of HD-induced hypoxemia in patients with COVID-19 and its effect on prognosis of COVID-19. Methods Eleven HD patients admitted with COVID-19 from August 2020 to April 2021 were classified into the patients whose oxygen demand increased by more than 3 L/min with mask during HD (worsened group, n = 5) and others (not-worsened group, n = 6). The background, laboratory findings, severity of COVID-19 and prognosis were compared between the two groups. In addition, blood gases were measured before and after dialysis among HD patients admitted with COVID-19 on April 2021 (n = 3). Results There were no significant differences in backgrounds, except for a higher proportion of diabetes mellitus in worsened group (p = 0.04). Although laboratory findings were not significantly different on admission day, albumin and LDH levels 7 days after admission were significantly lower and higher in worsened group, respectively (p = 0.03 and < 0.01). The severity of COVID-19 and survival rate were significantly worse in worsened group (p = 0.01 and 0.03). The alveolar-arterial oxygen pressure difference (Aa-DO2) opened during HD in a patient with HD-induced hypoxemia, but did not open in patients without HD-induced hypoxemia. Conclusions There is a close relationship among HD-induced hypoxemia and poor prognosis of COVID-19. The HD-induced hypoxemia of patients with COVID-19 may be caused by ventilation/perfusion mismatching.

Từ khóa


Tài liệu tham khảo

Frantzen L, Cavaille G, Thibeaut S, El-Haik Y. Efficacy of the BNT162b2 mRNA Covid-19 Vaccine in a hemodialysis cohort. Nephrol Dial Transplant. 2021;36:1756.

Angeletti A, Zappulo F, Donadei C, Cappuccilli M, Di Certo G, Conte D, et al. Immunological effects of a single hemodialysis treatment. Medicina (Kaunas). 2020;56(2):71.

Haarhaus M, Santos C, Haase M, Mota Veiga P, Lucas C, Macario F. Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: implications for management of the pandemic in outpatient hemodialysis settings. Clin Kidney J. 2021;14(3):805–13.

Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–29.

Quiroga B, Muñoz Ramos P, Giorgi M, de Santos A, Núñez A, Ortiz A, et al. Dynamic assessment of interleukin-6 during hemodialysis and mortality in coronavirus disease-19. Ther Apher Dial. 2021.

Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med. 1977;296(14):769–74.

Campos I, Chan L, Zhang H, Deziel S, Vaughn C, Meyring-Wösten A, et al. Intradialytic hypoxemia in chronic hemodialysis patients. Blood Purif. 2016;41(1–3):177–87.

Han Y, Zhang H, Mu S, Wei W, Jin C, Tong C, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY). 2020;12(12):11245–58.

Manolis AS, Manolis TA, Manolis AA, Papatheou D, Melita H. COVID-19 infection: viral macro- and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management. J Cardiovasc Pharmacol Ther. 2021;26(1):12–24.

McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127(4):571–87.

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.

Eloueyk AK, Alameddine RY, Osta BA, Awad DM. Correlations between serum inflammatory markers and comorbidities in patients with end-stage renal disease. J Taibah Univ Med Sci. 2019;14(6):547–52.

Almeida A, Lourenço O, Fonseca AM. Haemodialysis in diabetic patients modulates inflammatory cytokine profile and T cell activation status. Scand J Immunol. 2015;82(2):135–41.

Goicoechea M, Sánchez Cámara LA, Macías N, Muñoz de Morales A, Rojas ÁG, Bascuñana A, et al. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. Kidney Int. 2020;98(1):27–34.

Kocak SY, Kayalar AO, Karaosmanoglu HK, Yilmaz M. COVID-19 in hemodialysis patients: a single-center experience in Istanbul. Int Urol Nephrol. 2021;53(11):2385–97.

Thông tin
Thông tin xuất bản

Renal Replacement Therapy

Tập 8 Số 1

Thông tin tác giả